Histone deacetylase inhibitor MGCD0103 causes cell cycle arrest, apoptosis, and autophagy in liver cancer cells
Authors:
Open Access
- 1 January 2020
- journal article
- research article
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 11 (7) , 1915-1926
Abstract
Background: Liver cancer is a common cause of cancer-related death all over the world. MGCD0103, a histone deacetylase inhibitor, exerts antitumor effect on various cancers. However, its role in liver cancer remains unclear.Keywords
This publication has 34 references indexed in Scilit:
- Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemiaLeukemia, 2014
- Epigenetic therapy of cancer with histone deacetylase inhibitorsJournal of Cancer Research and Therapeutics, 2014
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trialThe Lancet Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Gallic Acid Induces G2/M Phase Arrest of Breast Cancer Cell MCF-7 through Stabilization of p27Kip1 Attributed to Disruption of p27Kip1/Skp2 ComplexJournal of Agricultural and Food Chemistry, 2011
- Antimetastatic Role of Smad4 Signaling in Colorectal CancerGastroenterology, 2010
- Histone Deacetylase Inhibitors in Cancer TherapyJournal of Clinical Oncology, 2009
- Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009The Lancet Oncology, 2009
- Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme AssayClinical Cancer Research, 2008
- p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell deathJournal of Cell Biology, 2005